BCAT2 and diabetic cardiomyopathy: Increased plasma and myocardial BCAAs have also been found in a diabetic cardiomyopathy mouse model with reduced expression of BCAT2, where pyridostigmine induced BCAA metabolism and clearance and attenuated the formation of myocardial scar tissue (Yang et al, 2021).